The role of the CYP1A1 gene in long-term glucocorticoid-related adverse effects
Authors' conclusion
The CYP1A1 rs1799814 polymorphism is associated with more severe GC-related AE, suggesting reduced GC metabolism.
Study context
- Population
- Patients receiving chronic GC treatment (≥5 mg/day for >3 months) (56 ± 16.6 years; 71.4% female; 47.1% postmenopausal)patients receiving chronic GC treatment included
- Participants
- 70 patients
- Comparison
- Patients with vs without the CYP1A1 rs1799814 polymorphism
- rs1799814 polymorphismn = nine
- Outcome
- CYP1A1 polymorphisms identified
Methodological details5 years of follow-up, CYP1A1 gene sequencing by NGS using Amplicon Deep Sequencing on an Ion Torrent platform
- 5 years of follow-up
- CYP1A1 gene sequencing by NGS using Amplicon Deep Sequencing on an Ion Torrent platform
Main finding
As reported in the abstract
- rs1048943
- Nine patients
- rs1799814
- nine
- rs4646422
- one
- rs41279188
- one
Further findings
NTx · lower with rs1799814
P = 0.003
CTx
P = 0.068
OC
P = 0.059
| Outcome | rs1799814 polymorphism | Without rs1799814 | P value |
|---|---|---|---|
| BMIHigher BMI with rs1799814 | 29.3 | 25.5 | P = 0.019 |
| BMI change (ΔBMI) · 5 yearsGreater BMI change with rs1799814 · adjusted for cumulative GC dose | 1.7 | −0.32 | P = 0.02 |
Osteoporosis and/or fractures, bone mineral density (BMD) or trabecular bone score (TBS) values
- No associations were found between CYP1A1 polymorphisms and the presence of osteoporosis and/or fractures, BMD or TBS values
Original publication
The role of the CYP1A1 gene in long-term glucocorticoid-related adverse effects. Osteoporos Int. Published 27 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →